Current Report Filing (8-k)
19 March 2020 - 7:08AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of Report (Date of earliest event
reported): March 18, 2020
NEMAURA MEDICAL INC.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
001-38355
|
|
46-5027260
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
57 West 57th Street
Manhattan,
NY
|
10019
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
Registrant’s telephone number, including area code:
|
+1
(646) 416-8000
|
N/A
(Former name or former address, if changed since
last report)
|
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12(b) under
the Exchange Act (17 CFR 240.14a-12(b))
[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
NMRD
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act
of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01.
|
Regulation FD Disclosure.
|
On March 18, 2020, Nemaura Medical Inc. issued
a press release providing certain business updates. A copy of the press release is attached as Exhibit 99.1 hereto.
The information included in this Current Report
on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such
information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall
not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed
solely to satisfy the requirements of Regulation FD.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 18, 2020
|
Nemaura Medical Inc.
|
|
|
|
By:
|
/s/ Dewan F. H. Chowdhury
|
|
Name:
Title:
|
Dewan F. H. Chowdhury
Chief Executive Officer
|
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2024 to May 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From May 2023 to May 2024